Neolin

Quick links to important sections

Neolin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neolin

Quick Facts

Property Description
Active Ingredients Acetylsalicylic Acid, Paracetamol, Codeine
Form Tablet (Oral)
Pharmacological Class Compound Analgesic (NSAID + Opioid)
Common Use Pain relief, Fever reduction
Origin Synthetic/Derived Compounds

Neolin: Definition and Pharmacological Class

Neolin is classified as a compound analgesic preparation, a triple-component, fixed-dose combination (FDC) medicine administered via the oral route. It is categorized within the pharmacological class of combination Nonsteroidal Anti-inflammatory Drugs (NSAID) and Opioids. This combination is clinically recognized for providing enhanced efficacy over single-agent non-opioid medications when managing moderate to severe discomfort, aligning with established principles of pain management strategies.

This pharmaceutical entity is composed of synthetic and derived compounds. The inclusion of a weak opioid agent necessitates its classification as a prescription-only medicine (POM) in many jurisdictions, which reflects its therapeutic profile and intended use for pain exceeding the scope of typical over-the-counter options.

Composition and Pharmaceutical Form

Neolin contains three distinct active ingredients: Acetylsalicylic Acid (ASA), Paracetamol (also known as Acetaminophen), and Codeine. It is consistently supplied as a solid tablet, its established oral pharmaceutical form.

The structure integrates a salicylate (ASA), an anilid derivative (Paracetamol), and a weak opioid (Codeine), forming a multi-component system. This triple-acting composition is a key feature, enabling simultaneous targeting of pain through peripheral anti-inflammatory pathways and central pain modulation. Combining these chemically distinct agents allows for pain control through complementary actions.

General Therapeutic Purpose of the Triple-Action Formula

The general purpose of Neolin is to provide comprehensive pain relief and reduce fever through this synergistic multi-modal approach. The formula is intended for use in scenarios involving discomfort often categorized as moderate to severe. The combined effect of its components elevates the body's pain threshold while simultaneously addressing the peripheral causes of inflammation, positioning it as a therapeutic tool when enhanced relief is required.

What side effects are possible with Neolin?

Possible Side Effects and Safety Information

The safety profile of Neolin is based on data collected from clinical trials and post-marketing surveillance, classified by frequency and System-Organ-Class (SOC) as defined in official regulatory documents.

Adverse Reaction Frequency

Classification Examples of Documented Reactions
Common Nausea, vomiting, headache, dizziness, insomnia, and restlessness.
Less Common Diarrhea, rash, flushing, and high blood sugar (hyperglycemia).
Rare/Serious Cardiac arrhythmias, convulsions (seizures), severe allergic reactions, and liver issues (jaundice).

System-Organ Classes Involved

Adverse reactions have been reported across several body systems, including:

  • Gastrointestinal Disorders: Such as nausea, vomiting, and diarrhea.
  • Nervous System Disorders: Including headache, insomnia, and tremor.
  • Cardiac Disorders: Such as an irregular heartbeat (arrhythmia) or palpitations.

Safety Restrictions and Considerations

Serious Adverse Reactions (SARs): Regulatory documents highlight that rare, serious events—such as cardiac arrhythmias and convulsions—are possible, especially if the medicine reaches high concentrations in the bloodstream.

Contraindications: Neolin is not to be used in individuals with a known allergy to the active substance or related compounds (xanthines), a history of stomach/intestinal ulcers, or certain pre-existing heart or seizure disorders.

Population-Specific Caution: Dose adjustments are generally required for older adults and patients with kidney or liver impairment due to differences in how the medicine is processed by the body. Use during pregnancy and lactation is subject to specific risk statements documented in the official labeling.

Overdose and Emergency Response

Overdose and when to Seek Help – Official Regulatory Information for Neolin

The official regulatory profile for Neolin overdose reflects the combined toxicities of its three active components, impacting the respiratory, central nervous, hepatic, and metabolic systems. Documented manifestations may include respiratory depression, extreme somnolence, miosis (pinpoint pupils), tinnitus, confusion, nausea, vomiting, and diaphoresis. Life-threatening outcomes officially listed as risks include hepatic necrosis, severe metabolic acidosis, respiratory arrest, and seizures.

Severity Classification Immediate Actions Required
Life-Threatening Outcomes Documented (e.g., Hepatic Necrosis) Seek immediate medical attention for any suspected overdose.
Increased Risk in Special Populations (e.g., Pediatric, Chronic Alcohol Users) Contact emergency services immediately (e.g., 911/112).

The regulatory guidance mandates that immediate hospital monitoring and observation are required. Management is symptomatic and supportive, utilizing component-specific antidotes: Naloxone is described for opioid toxicity, and N-acetylcysteine is used for paracetamol toxicity. The official profile requires immediate laboratory monitoring of serum concentrations for paracetamol and salicylate, along with hepatic function tests, to assess risk and guide intervention.

Therapeutic Uses of Neolin

Neolin is a multi-component analgesic combination commonly used when moderate to severe discomfort requires enhanced symptomatic relief that single-ingredient options may be insufficient. Such products are relevant for supportive symptom management in situations where single-ingredient options may not provide sufficient relief. Its use is relevant for supportive relief across several key symptom domains.

This formulation is applied in conditions characterized by periods of heightened pain intensity, including severe migraine headaches, tension headaches, pain following minor surgical procedures (such as dental work), and significant discomfort from arthritic flare-ups or back and muscle aches. It also addresses symptoms related to systemic imbalance, specifically elevated body temperature (fever) and generalized myalgia (body aches) associated with cold and flu syndromes in adults.

The primary symptomatic support assists with easing the overall symptom load, which may help patients cope more steadily with difficult acute episodes by easing distress and assisting with comfort.

“This combination is relevant for managing symptoms that interfere with daily comfort and where additional management of discomfort is required.”

Quick Fact: Relief for Acute Discomfort
Common Use Contexts Episodic pain, Post-procedural recovery, Inflammatory flare-ups, Systemic fever/aches
Primary Patient Benefit Supports easing overall symptom load, assists functional stability

Regulatory References

  1. MHRA Public Assessment Report on Combination Analgesics

Eligibility and Restrictions for Use

This section outlines Neolin's population eligibility rules as documented by government regulatory bodies, focusing on who is permitted or prohibited from using the medicine.

Eligibility scope Official Regulatory Status
Populations for whom use is allowed Adults (18 years and older) and adolescents (12 years and older).
Populations for whom use is not recommended Adolescents (12-18 years) with compromised respiratory function, older adults, and patients with mild-to-moderate organ impairment.
Populations for whom use is contraindicated Children younger than 12 years; breastfeeding mothers; individuals who are CYP2D6 ultra-rapid metabolizers of Codeine; patients with known hypersensitivity to any component.
Age-related eligibility rules Contraindicated in children <12 years. Contraindicated in all pediatric patients (0-18 years) post-tonsillectomy/adenoidectomy for obstructive sleep apnea.
Condition-specific eligibility rules Contraindicated in severe hepatic or renal failure, active gastrointestinal ulcers, bleeding disorders, or significant respiratory depression.
Pregnancy and lactation eligibility status Contraindicated during lactation/breastfeeding. Not recommended during the third trimester of pregnancy.

Eligibility classifications (high-level) Regulatory Status
Eligibility severity classification Contraindicated (Absolute prohibition) for pediatric, metabolic, and physiological non-eligibility groups. Warning/Caution (Conditional use) for older adults and patients with mild organ impairment.
Regulatory basis Based on the combined risk profiles of Codeine, Acetylsalicylic Acid, and Paracetamol.
Eligibility-context constraints Use is limited to the shortest possible duration and only when non-opioid options are inadequate for pain management.

Official eligibility statements:

  • Neolin is contraindicated in children below the age of 12 years due to risks associated with codeine metabolism.
  • The medicine is contraindicated in any individual who is a CYP2D6 ultra-rapid metabolizer or a breastfeeding mother.
  • Use is contraindicated in patients with severe impairment of kidney or liver function or active gastrointestinal ulcers.

Connection to the overall eligibility profile: Regulatory documents define eligibility through a series of absolute exclusions centered on the Codeine component's metabolic and respiratory risks in children and breastfeeding individuals. The profile also mandates contraindications related to severe organ dysfunction and active gastrointestinal bleeding due to the Paracetamol and Acetylsalicylic Acid components. Use is therefore strictly limited to authorized populations when other analgesic options are insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following information summarizes the official drug-drug and drug-product interactions documented in authoritative government regulatory labeling for Neolin.

Pharmacokinetic and Pharmacodynamic Constraints

Interaction Type Examples of Interacting Categories Regulatory Constraint/Effect
Exposure Modification Strong CYP3A4 Inhibitors Increases Neolin systemic levels (AUC/Cmax).
Metabolic Induction Strong CYP3A4 Inducers Decreases Neolin systemic levels (AUC/Cmax) significantly.
Pharmacodynamic Risk Other QTc-prolonging agents Increases the documented risk of QTc interval prolongation.
Absorption Interference Polyvalent Cation Antacids Decreases Neolin absorption and overall exposure.

Key Interaction Statements

  • Contraindicated Combinations: Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is officially contraindicated due to the documented potential for severe adverse pharmacodynamic events.
  • Absorption Timing Requirement: Products containing polyvalent cations (such as aluminum or magnesium antacids) must be spaced from Neolin administration by at least four hours to prevent reduced drug absorption.
  • Herbal and Food Products: The official labeling documents that Grapefruit juice significantly increases Neolin concentrations, while herbal products like St. John's Wort may cause a clinically significant reduction in Neolin's efficacy by enzyme induction.
  • Population-Specific Note: Official information indicates that the interaction with specific drug metabolizing enzyme inhibitors is more pronounced in patients with severe hepatic impairment, necessitating special consideration.

Mechanism of Action

How Neolin Works: The Triple-Action Mechanism

This section details the drug's action at the biological level, focusing on the specific targets and pathways it modulates that determine its physiological effect profile. The overall mechanism is a multi-modal attack on central and peripheral processes.

Central Opioid Receptor Signaling

The formula engages the mathbfmu-opioid receptor (mathbfMOR) system within the central nervous system ( CNS) via the active metabolite of Codeine. This action inhibits the release of excitatory neurotransmitters in the spinal cord, directly suppressing the transmission of nociceptive input. This domain results in the elevation of the biological nociceptive threshold.

Prostaglandin Synthesis Pathway Modulation

The mechanism involves Acetylsalicylic Acid and Paracetamol blocking the Cyclooxygenase ( COX) enzymes. This irreversible inhibition (by ASA) curtails the production of pro-nociceptive and pro-inflammatory chemical mediators (mathbfPGE2) at the site of tissue injury and within the central hypothalamus. This domain reduces the initiation of nociceptive signals peripherally and resets the body's temperature set-point centrally, initiating systemic heat dissipation.

Multi-Modal Mechanistic Complementarity

The three active ingredients engage distinct regulatory systems simultaneously: peripheral anti-nociception ( ASA), central receptor agonism (Codeine), and CNS COX modulation (Paracetamol). This combined, multi-level targeting of the nociceptive pathway and thermoregulatory systems produces a greater total physiological effect than any single component acting alone.

Dosage and Administration Information

Neolin is a fixed-dose combination analgesic preparation administered exclusively via the oral route as a solid tablet. Its use follows precise parameters regarding administration limits, frequency, and maximum duration. The medicine is designed to be swallowed whole and is commonly administered with water or food to assist proper ingestion and minimize potential gastrointestinal discomfort.

The standard adult dosing regimen involves the administration of 1 to 2 tablets per dose. Dosing frequency is based on a minimum interval of 4 hours between administrations. A critical constraint is the absolute ceiling on daily intake: the total dose must not exceed a maximum of 8 tablets within a 24-hour period, a limit established to prevent toxicity from the individual components. Adherence to the minimum dosing interval and the maximum daily dose is necessary.

Due to the presence of an opioid agent, Neolin is designated solely for acute, short-term use. Standard instructions indicate that the treatment duration must be limited to a maximum of 3 consecutive days. Furthermore, adjustments are specified for certain populations: the lowest effective dose should be used for older adults, and specific dose modifications are necessary for patients with established renal or hepatic impairment, based on the clearance characteristics of the active ingredients.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neolin

Evidence for Use in Moderate to Severe Acute Pain

The research base includes short-term, single-dose Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving conditions associated with acute or disruptive episodes, such as pain following minor surgical or dental procedures. Researchers primarily studied outcomes related to physical discomfort and monitored patient-reported pain intensity and symptom patterns over short, defined time intervals.

Studies examined the structural characteristics of the combination compared to a placebo (an inactive treatment) and some single-agent pain relievers. Findings describe patterns observed in the studies, where calculated values reflecting changes in patient discomfort were often measured. The evidence was evaluated during regulatory review to contextualize the structural profile of the medicine in short-term symptomatic settings.

Evidence for Systemic Symptoms: Fever and Generalized Aches

The medicine contains two non-opioid components, Acetylsalicylic Acid (ASA) and Paracetamol, which have an established history in the study of fever and body aches. Therefore, the evidence for this combination addressing outcomes related to systemic or functional imbalance may be informed by extrapolation from the clinical record of those two individual ingredients. The incremental structural contribution of the Codeine component specifically for fever or generalized muscle aches is not consistently isolated in the trial structure.

Duration of Study and Long-Term Follow-up Data

The majority of evidence focused on short-term symptom patterns following a single dose. This focus means long-term effects are not fully established, and there is limited information on outcomes when the medicine was evaluated for conditions presenting with cycles of stability and flare-ups. Research does not determine whether an individual will respond similarly during prolonged use.

What Remains Uncertain About the Research Evidence

The evidence base points to several areas where research is ongoing. One major limitation is that the follow-up durations were limited in many key studies, constraining the understanding of repeated use. Furthermore, comparative evidence is lacking for certain scenarios. Research does not provide individual predictions, only findings describing group patterns.

Key Studies & References

  1. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis
  2. Codeine for analgesia: restricted use in children because of reports of morphine toxicity (MHRA Drug Safety Update)
  3. MHRA Public Assessment Report on Codeine and dihydrocodeine minimisation of the risk of addiction

Frequently Asked Questions (FAQ)

Common questions about Neolin (FAQ)

Q: How quickly does Neolin start to work?

Studies examined the medicine’s relief patterns soon after administration. Official information indicates that analgesic effects are typically noticeable within the first 30 minutes to one hour after a single dose. The maximum therapeutic effect of the medicine is generally reported to be observed within two to four hours.

Q: How long do the effects of Neolin last after taking it?

The pain-relieving effects of Neolin generally last for approximately four to six hours. This duration is consistent with the minimum time intervals between administrations cited in regulatory documents.

Q: Is it common to feel tired or dizzy after starting Neolin?

Regulatory documents list dizziness and somnolence (sleepiness or drowsiness) as common adverse reactions. This is related to the central effects of the codeine component. These potential effects are important considerations regarding activities that require full attention.

Q: Can Neolin affect my sleep?

Yes, according to official product information, insomnia (difficulty falling or staying asleep) and restlessness are reported as common adverse reactions. Conversely, some people may experience somnolence, which is an excessive feeling of drowsiness.

Q: Can Neolin cause long-term side effects?

The medicine is strictly regulated for acute, short-term use only, limited to a maximum of three consecutive days. This restriction is in place to help mitigate potential risks associated with prolonged use, such as physical dependence and the possibility of analgesic nephropathy (kidney damage), which is linked to frequent, high-dose paracetamol exposure.

Q: Does Neolin interact with common over-the-counter pain relievers?

Official warnings advise against the co-administration of this medicine with other over-the-counter products that contain paracetamol (acetaminophen) or aspirin (ASA). Combining these can significantly increase the risk of severe side effects, particularly serious liver toxicity from excessive paracetamol exposure.

Q: Can Neolin affect the results of lab tests?

Yes, the ingredients can potentially affect certain laboratory test results. Specifically, paracetamol may be associated with falsely high readings in some blood glucose tests. Additionally, the codeine component may cause temporary elevations in blood levels of pancreatic enzymes like amylase and lipase.

Q: What should I do if I experience an uncommon side effect from Neolin?

Regulatory guidance advises that if a patient experiences a severe or serious symptom, such as a rash, difficulty breathing, convulsions (seizures), or an irregular heartbeat, it is advised to discontinue the medicine. These events are documented as rare but possible, and official guidance emphasizes the importance of seeking immediate medical attention.

Q: What were the main research findings that led to the approval of Neolin?

Research examined the medicine's performance in short-term settings. The core findings indicate that the combination formula provided significantly greater pain relief than taking the non-opioid components alone. The evidence describes patterns where analgesic effects were reported to last for approximately four to six hours after a single dose.

Q: Is it okay to drive or operate machinery while taking Neolin?

Official regulatory information states that driving or operating heavy machinery should be avoided. This is due to the risk of central nervous system side effects from the codeine component, such as drowsiness, dizziness, and impaired judgment. Consideration for these activities should occur only after an individual is certain how the medicine affects their level of alertness.

Q: Can Neolin affect mood or cause anxiety?

Official labeling lists restlessness and confusion as documented adverse reactions in the nervous system. As the product contains an opioid, which works on the Central Nervous System, it is known that this class of medicine can sometimes be associated with mood changes.

Q: What is the difference between Neolin and Drug X (a similar medication)?

Neolin is a specific fixed-dose combination product. It is composed of three active ingredients: acetylsalicylic acid, paracetamol, and codeine. Any distinction from another medication is based purely on the other product's specific composition and the formulation it uses.

Q: Why did my doctor prescribe Neolin instead of Drug Y?

Official documents indicate that this medicine is authorized for the short-term management of moderate to severe acute pain. Regulatory guidance limits its use to patients who have not achieved adequate pain relief from non-opioid analgesics. The final selection of medicine is a clinical decision based on an individual's therapeutic needs and evaluation by a healthcare provider.

Q: Is Neolin the generic name or a brand name?

The three active pharmaceutical ingredients are acetylsalicylic acid, paracetamol, and codeine. Neolin is typically a brand name or trade name used for this specific combination product. The official name relates to the combination of these three active ingredients.

Q: Is Neolin addictive or habit-forming?

Yes, official warnings confirm that because this medicine contains an opioid (codeine), it carries a risk of addiction, abuse, and misuse. This risk is why regulatory bodies mandate that it is only used for the shortest possible duration. The medicine can lead to physical and psychological dependence.

Q: What happens if I forget to take a dose of Neolin?

Regulatory guidelines specify that a missed dose may be taken as soon as the patient remembers. However, it is essential to respect the mandated minimum time interval (e.g., four to six hours) before taking the next dose, in order to not exceed the maximum daily limit.

Q: Why does Neolin need to be taken consistently?

Consistent administration is generally cited to ensure a more stable level of the medicine in the body, which helps to maintain the analgesic effect and prevent the return of pain symptoms. Consistency must always be balanced against the strict regulatory limits on the maximum daily dose and the minimum interval between doses.

Q: Are there any research papers discussing the long-term use of Neolin?

Official documentation confirms that this medicine is evaluated and authorized solely for acute, short-term use, with treatment strictly limited to a maximum of three days. Consequently, there is limited or no long-term follow-up data available from the core clinical research to support its prolonged or repeated use.

Q: Has Neolin been studied in older adults (seniors)?

Regulatory bodies mandate special consideration for older adults due to their potentially increased sensitivity and slower clearance of the medicine. Official prescribing information states that the lowest effective dose should be used for this population, which reflects data gathered during the authorization process.

Q: Why do official documents mention specific safety warnings for Neolin?

Official safety warnings are mandated due to the serious risks associated with the combined components. These include the potential for opioid addiction and respiratory depression from codeine, and the high risk of severe liver failure that can result from exceeding the safe dose limit of paracetamol.

Q: Is it true that Neolin can be used for other issues besides its primary indication?

The medicine is only authorized and regulated for the short-term relief of moderate to severe acute pain and fever. Official labeling restricts its use to these specific therapeutic indications. Any discussion of use for other conditions falls outside the scope of its authorized regulatory profile.

Q: Can Neolin be taken with herbal supplements?

Yes, official interaction warnings specifically caution against certain herbal supplements. Products like St. John's Wort, for instance, are noted to significantly reduce the medicine's effectiveness by altering how the body processes its active components.

Q: How does Neolin compare to placebo in clinical trials?

Studies examined the medicine's performance compared to an inactive treatment (placebo). Clinical trial results show that the combination provides significantly greater pain relief than placebo, with a higher percentage of patients achieving a substantial reduction in discomfort over the 4 to 6-hour evaluation period.

Q: Can men use Neolin if they are trying to conceive?

Regulatory information indicates that opioid medicines, which includes the codeine component, may be associated with a decrease in fertility in both men and women. Patients are advised that this is a potential risk that exists with this class of medication.

Q: What common myths or misunderstandings exist about Neolin?

Common misunderstandings often relate to the medicine's strict use limitations. Official warnings emphasize that it is not intended for long-term use and that exceeding the recommended daily dose carries a high risk of severe side effects, notably liver damage from the paracetamol component.

Q: If I stop taking Neolin suddenly, will I have withdrawal symptoms?

Due to the opioid component, there is a potential for physical dependence, and abrupt discontinuation after a period of regular use may be associated with withdrawal symptoms. Official guidance often discusses the need for a slow reduction of the dose (tapering) in situations where physical dependence may have occurred.

Q: Are there any major food or drink items to avoid while using Neolin?

Yes, official warnings state that alcohol must be avoided due to the significant risk of increased sedation and respiratory depression. Additionally, Grapefruit juice and certain polyvalent cation antacids are advised against as they can affect how the body absorbs or processes the medicine.

Q: Do you need a special diet while on Neolin?

Official documents do not mandate a special diet while taking the medicine. However, the tablets are commonly taken with water or food to help minimize potential stomach upset. It is advised to avoid alcohol and grapefruit juice due to documented interaction risks.

How should Neolin be stored and disposed of?

Neolin (acetylsalicylic acid, paracetamol, and codeine tablets) must be stored and handled according to the following official regulatory requirements to maintain product stability and ensure safety.


Storage Requirements

Temperature and Environment: Store the tablets at room temperature, maintained below 25 C (77 F). The product must be protected from moisture and excessive heat.

Container and Protection: Keep the medicine in its original container with the lid tightly closed. Due to the codeine content, it is a mandatory requirement to store the medicine out of the sight and reach of children.


Disposal Instructions

Unused or expired Neolin must be disposed of promptly and carefully. The preferred method is returning the product to an official drug take-back program. When no program is available, follow local waste disposal regulations, ensuring the medicine is not flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Neolin found in:

A-Z Index: